Internet Explorer 8 Warnung You seem to be using an outdated version of Internet Explorer. Please note that this site does not support this browser version (a href="">as does Microsoft). You may experience design inconsistencies and error messages. We are sorry for any inconveniences.

Portfolio Finder

Current Startups

Zimmer BioTech

As early as 2012, Zimmer contributed to the development of a drug based on the compound 5-Aminolevulinic acid for use in the treatment of actinic keratoses. The spin-off Zimmer BioTech has been active since October 2016 and is funded by Bonn-based High-Tech Gründerfonds, Germany’s largest seed stage investor. Alevin deep, the first drug to be developed by Zimmer BioTech, is expected to receive approval by 2020.

Info & Contact

+49 7 3197610


Zimmer MedizinSysteme GmbH
Junkersstraße 9
89231 Neu-Ulm

Added to portfolio

13. Jun 2017